CA Stock MarketDetailed Quotes

Medicenna Therapeutics Corp (MDNA)

Watchlist
  • 0.560
  • -0.100-15.15%
15min DelayMarket Closed May 14 16:00 ET
46.72MMarket Cap-3.73P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Medicenna Therapeutics Corp (MDNA) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Dec 31, 2025
(Q2)Sep 30, 2025
(Q1)Jun 30, 2025
(FY)Mar 31, 2025
(Q4)Mar 31, 2025
(Q3)Dec 31, 2024
(Q2)Sep 30, 2024
(Q1)Jun 30, 2024
(FY)Mar 31, 2024
(Q4)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
9.69%5.62M
-1.03%5.47M
36.36%5.51M
9.27%20.41M
42.94%5.72M
7.18%5.12M
1.66%5.53M
-9.40%4.04M
14.54%18.67M
34.67%4M
Selling and administrative expenses
1.13%1.52M
-24.96%1.34M
2.39%1.28M
-24.93%5.91M
-36.55%1.36M
-15.53%1.51M
-22.20%1.79M
-23.88%1.25M
12.51%7.87M
54.41%2.14M
-General and administrative expense
1.13%1.52M
-24.96%1.34M
2.39%1.28M
-24.93%5.91M
-36.55%1.36M
-15.53%1.51M
-22.20%1.79M
-23.88%1.25M
12.51%7.87M
54.41%2.14M
Research and development costs
13.39%4.07M
10.23%4.11M
51.22%4.21M
33.74%14.44M
133.17%4.34M
20.09%3.59M
18.89%3.73M
-1.07%2.78M
16.08%10.8M
17.47%1.86M
Depreciation amortization depletion
-9.52%19K
90.00%19K
280.00%19K
1,000.00%55K
1,800.00%19K
950.00%21K
900.00%10K
400.00%5K
0.00%5K
0.00%1K
-Depreciation and amortization
-9.52%19K
90.00%19K
280.00%19K
1,000.00%55K
1,800.00%19K
950.00%21K
900.00%10K
400.00%5K
0.00%5K
0.00%1K
Operating profit
-9.69%-5.62M
1.03%-5.47M
-36.36%-5.51M
-9.27%-20.41M
-42.94%-5.72M
-7.18%-5.12M
-1.66%-5.53M
9.40%-4.04M
-14.54%-18.67M
-34.67%-4M
Net non-operating interest income (expenses)
-69.84%114K
-58.20%158K
-38.18%204K
12.69%1.35M
15.79%264K
34.04%378K
10.53%378K
-4.62%330K
31.07%1.2M
-40.31%228K
Non-operating interest income
-69.84%114K
-58.20%158K
-38.18%204K
12.69%1.35M
15.79%264K
34.04%378K
10.53%378K
-4.62%330K
31.07%1.2M
-40.31%228K
Other net income (expenses)
353.45%1.14M
-56.45%429K
416.44%377K
190.75%7.25M
165.56%6.64M
6.85%-449K
-28.21%985K
-94.16%73K
-249.60%-7.99M
-699.61%-10.13M
Gain on sale of security
353.45%1.14M
-56.45%429K
416.44%377K
190.75%7.25M
165.56%6.64M
6.85%-449K
-28.21%985K
-94.16%73K
-249.60%-7.99M
-699.61%-10.13M
Income before tax
15.93%-4.36M
-17.27%-4.88M
-35.50%-4.93M
53.64%-11.81M
108.54%1.19M
-4.30%-5.19M
-11.85%-4.16M
-27.08%-3.64M
-153.44%-25.47M
-260.58%-13.9M
Income tax
Earnings from equity interest net of tax
Net income
15.93%-4.36M
-17.27%-4.88M
-35.50%-4.93M
53.64%-11.81M
108.54%1.19M
-4.30%-5.19M
-11.85%-4.16M
-27.08%-3.64M
-153.44%-25.47M
-260.58%-13.9M
Net income continuous operations
15.93%-4.36M
-17.27%-4.88M
-35.50%-4.93M
53.64%-11.81M
108.54%1.19M
-4.30%-5.19M
-11.85%-4.16M
-27.08%-3.64M
-153.44%-25.47M
-260.58%-13.9M
Noncontrolling interests
Net income attributable to the company
15.93%-4.36M
-17.27%-4.88M
-35.50%-4.93M
53.64%-11.81M
108.54%1.19M
-4.30%-5.19M
-11.85%-4.16M
-27.08%-3.64M
-153.44%-25.47M
-260.58%-13.9M
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders
15.93%-4.36M
-17.27%-4.88M
-35.50%-4.93M
53.64%-11.81M
108.54%1.19M
-4.30%-5.19M
-11.85%-4.16M
-27.08%-3.64M
-153.44%-25.47M
-260.58%-13.9M
Diluted earnings per share
28.57%-0.05
-20.00%-0.06
-20.00%-0.06
59.46%-0.15
110.00%0.02
0.00%-0.07
0.00%-0.05
-25.00%-0.05
-131.25%-0.37
-233.33%-0.2
Basic earnings per share
28.57%-0.05
-20.00%-0.06
-20.00%-0.06
59.46%-0.15
110.00%0.02
0.00%-0.07
0.00%-0.05
-25.00%-0.05
-131.25%-0.37
-233.33%-0.2
Dividend per share
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Dec 31, 2025(Q2)Sep 30, 2025(Q1)Jun 30, 2025(FY)Mar 31, 2025(Q4)Mar 31, 2025(Q3)Dec 31, 2024(Q2)Sep 30, 2024(Q1)Jun 30, 2024(FY)Mar 31, 2024(Q4)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 9.69%5.62M-1.03%5.47M36.36%5.51M9.27%20.41M42.94%5.72M7.18%5.12M1.66%5.53M-9.40%4.04M14.54%18.67M34.67%4M
Selling and administrative expenses 1.13%1.52M-24.96%1.34M2.39%1.28M-24.93%5.91M-36.55%1.36M-15.53%1.51M-22.20%1.79M-23.88%1.25M12.51%7.87M54.41%2.14M
-General and administrative expense 1.13%1.52M-24.96%1.34M2.39%1.28M-24.93%5.91M-36.55%1.36M-15.53%1.51M-22.20%1.79M-23.88%1.25M12.51%7.87M54.41%2.14M
Research and development costs 13.39%4.07M10.23%4.11M51.22%4.21M33.74%14.44M133.17%4.34M20.09%3.59M18.89%3.73M-1.07%2.78M16.08%10.8M17.47%1.86M
Depreciation amortization depletion -9.52%19K90.00%19K280.00%19K1,000.00%55K1,800.00%19K950.00%21K900.00%10K400.00%5K0.00%5K0.00%1K
-Depreciation and amortization -9.52%19K90.00%19K280.00%19K1,000.00%55K1,800.00%19K950.00%21K900.00%10K400.00%5K0.00%5K0.00%1K
Operating profit -9.69%-5.62M1.03%-5.47M-36.36%-5.51M-9.27%-20.41M-42.94%-5.72M-7.18%-5.12M-1.66%-5.53M9.40%-4.04M-14.54%-18.67M-34.67%-4M
Net non-operating interest income (expenses) -69.84%114K-58.20%158K-38.18%204K12.69%1.35M15.79%264K34.04%378K10.53%378K-4.62%330K31.07%1.2M-40.31%228K
Non-operating interest income -69.84%114K-58.20%158K-38.18%204K12.69%1.35M15.79%264K34.04%378K10.53%378K-4.62%330K31.07%1.2M-40.31%228K
Other net income (expenses) 353.45%1.14M-56.45%429K416.44%377K190.75%7.25M165.56%6.64M6.85%-449K-28.21%985K-94.16%73K-249.60%-7.99M-699.61%-10.13M
Gain on sale of security 353.45%1.14M-56.45%429K416.44%377K190.75%7.25M165.56%6.64M6.85%-449K-28.21%985K-94.16%73K-249.60%-7.99M-699.61%-10.13M
Income before tax 15.93%-4.36M-17.27%-4.88M-35.50%-4.93M53.64%-11.81M108.54%1.19M-4.30%-5.19M-11.85%-4.16M-27.08%-3.64M-153.44%-25.47M-260.58%-13.9M
Income tax
Earnings from equity interest net of tax
Net income 15.93%-4.36M-17.27%-4.88M-35.50%-4.93M53.64%-11.81M108.54%1.19M-4.30%-5.19M-11.85%-4.16M-27.08%-3.64M-153.44%-25.47M-260.58%-13.9M
Net income continuous operations 15.93%-4.36M-17.27%-4.88M-35.50%-4.93M53.64%-11.81M108.54%1.19M-4.30%-5.19M-11.85%-4.16M-27.08%-3.64M-153.44%-25.47M-260.58%-13.9M
Noncontrolling interests
Net income attributable to the company 15.93%-4.36M-17.27%-4.88M-35.50%-4.93M53.64%-11.81M108.54%1.19M-4.30%-5.19M-11.85%-4.16M-27.08%-3.64M-153.44%-25.47M-260.58%-13.9M
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders 15.93%-4.36M-17.27%-4.88M-35.50%-4.93M53.64%-11.81M108.54%1.19M-4.30%-5.19M-11.85%-4.16M-27.08%-3.64M-153.44%-25.47M-260.58%-13.9M
Diluted earnings per share 28.57%-0.05-20.00%-0.06-20.00%-0.0659.46%-0.15110.00%0.020.00%-0.070.00%-0.05-25.00%-0.05-131.25%-0.37-233.33%-0.2
Basic earnings per share 28.57%-0.05-20.00%-0.06-20.00%-0.0659.46%-0.15110.00%0.020.00%-0.070.00%-0.05-25.00%-0.05-131.25%-0.37-233.33%-0.2
Dividend per share
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +3.66%
Sample Name
Sample Code
 +3.21%
Sample Name
Sample Code
 +1.57%
4
SINOPEC CORP
00386
+0.66%
5
CNOOC
00883
+0.53%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +47.30%
Sample Name
Sample Code
 +42.24%
Sample Name
Sample Code
 +30.17%
4
Loongson Technology Corporation
688047
+19.58%
5
Digital China Group
000034
+16.92%
View More
Middle East conflict spreads to the stock market! How should investors respond?
According to Axios, on Sunday local time, Trump rejected Iran's latest ceasefire proposal, prompting a sharp response from Iran: no one woul Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -